Drugs / Vi-DT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02645032 | May 2016 → Feb 2017 | typhoid fever | International Vaccine Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vi-DT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02645032 ↗ |
| Modality | Vaccine | “A typhoid conjugate vaccine composed of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) has been developed.” PMID 29776750 ↗ Jun 2018 |
| Route | Intramuscular | “Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).” NCT02645032 ↗ |